News

The new patent contains a composition of matter claim covering the use of the company’s ion exchange formulation of benzonatate. Claims for using benzonatate polacrilex to reduce or

Initially, the deal will focus on the development of the WT1 vaccine to treat leukemia, mesothelioma, and multiple myeloma, followed by additional solid tumor indications. In order to

Ipafricept is a first-in-class fusion protein that inhibits a key signaling pathway in cancer, the Wnt pathway. The FDA removed the partial clinical hold, after the company submitted

The MAA is based on the positive results from the data collected in Japan as part of the Phase III VIBRANT trial. The trial, which met its primary

The trial is designed to assess the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of CB-5083 in multiple myeloma patients who have relapsed/refractory or refractory disease after receiving two

This patent is entitled "Method of Synthesis of Substituted Hexitols Such as Dianydrogalactitol," and provides a patent term that lasts until 2030. "This allowance represents our second U.S.

A master drug file contains all of the information that regulatory agencies require as part of the drug development and approval process. Such information includes preclinical data, GMP

SPCD is an alternative method for conducting well-controlled clinical trials that substantially decreases the impact on trial outcomes of any placebo effect and will enable PPD’s clients to

The patent covers CPMA, a new polymer drug delivery platform technology developed by Rexahn. "We are pleased to further expand our platform of proprietary drug delivery technologies in